• Explore /
  • Poster
  • / Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 and mFOLFOX6 in patients with advanced gastric/gastroesophageal junction cancer.

Updated results of a phase 1 study combining the matrix metalloproteinase 9 inhibitor GS-5745 and mFOLFOX6 in patients with advanced gastric/gastroesophageal junction cancer.

Abstract Poster

Authors

Manish Shah

Manish A. Shah

Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY

Manish A. Shah , Alexander Starodub , Jordan Berlin , Carrie Baker Brachmann , Xi Huang , Victoria Smith , Julia D. Maltzman , Zev A. Wainberg , Johanna C. Bendell

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2017 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session A: Cancers of the Esophagus and Stomach

Track

Cancers of the Esophagus and Stomach

Sub Track

Multidisciplinary Treatment

Clinical Trial Registration Number

NCT01803282

Citation

J Clin Oncol 35, 2017 (suppl 4S; abstract 108)

DOI

10.1200/JCO.2017.35.4_suppl.108

Abstract #

108

Poster Bd #

H20

Abstract Disclosures

Similar Posters

First Author: Johanna C. Bendell

First Author: Xiangrui Meng

First Author: Neil J. Shah

Poster

2019 Gastrointestinal Cancers Symposium

Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).

Phase I results from the phase 1/3 FIGHT study evaluating bemarituzumab and mFOLFOX6 in advanced gastric/GEJ cancer (GC).

First Author: Mohamedtaki Abdulaziz Tejani